Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 5Phase 3 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 46Neoplasms 43Multiple Myeloma 41Stomach Neoplasms 34Lung Neoplasms 32Ovarian Neoplasms 31Neoplasm Metastasis 31Leukemia, Myeloid, Acute 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Triple Negative Breast Neoplasms 25Recurrence 25Pancreatic Neoplasms 25Small Cell Lung Carcinoma 21Esophageal Neoplasms 21Brain Neoplasms 21Uterine Cervical Neoplasms 20Colonic Neoplasms 20Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Smoldering Multiple Myeloma × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡